Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- New risk-prediction guideline: Headed in the right direction, but limitations persist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
-
- AstraZeneca to assess Brilinta in patients with diabetes, ischemic stroke
- ESC cautions against inappropriate radiation exposure
- Excess sodium intake prevalent in US adults
- Medtronic initiates human trial of small, minimally invasive pacemaker
- FDA approves CoreValve for patients with severe aortic stenosis
- Genetic variants that increase HDL levels do not decrease risk for MI Calvin W. Roberts, MD; Robert Roberts, MD, FRSC, FRCPC, MACC, LLD (Hon.), FAHA; William L. Roberts, MHA, CPA; Brandon A. Roberts, MSc, MD
- Adhesive patch monitor superior to Holter for prolonged arrhythmia tracking
- AHA: Stroke deaths on decline in United States
-
- COURAGE trial affected geographic variation in PCI
- Experts outline measures to improve quality of PCI
- Herpes zoster increased risk for stroke, TIA, MI in young people
- Increased rates of LVAD pump thrombosis reported at 3 centers
- Limited evidence supports multivitamins for CVD, cancer prevention
- New oral anticoagulants show favorable safety, efficacy vs. warfarin
- Smoking cessation therapies do not increase risk for serious CVD events
- Societies release overview of transcatheter MR therapies
-
- Transplant recipients of undersized hearts at greater risk for mortality
- TTE with contrast yielded lower mortality than non-contrast TTE in critically ill patients
- Preoperative prophylaxis decreased rate of SSIs
- Barry H. Greenberg, MD: Expert on HF at the cellular level
- Bioabsorbable scaffold yielded promising 3-year results
- GPAD-II: Cell therapy may improve walking performance in patients with PAD
- Medication reminder texts improved antiplatelet therapy adherence
- OSLER: PCSK9 inhibitor reduced LDL at 1 year
-
- VISTA-16: Varespladib linked to greater incidence of MI in ACS patients
- Clinical trial data provide 'divergent' conclusions about pharmacogenomic-guided warfarin dosing William L. Baker, PharmD, FCCP, BCPS (AQ Cardiology); Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
- Resistant hypertension: A growing issue, novel devices on the horizon
- HIPARCO
- MINERVA
- RE-COVER II
- RHYTHM-AF
- SWAP-2
-
- TRANSFUSION-2
- VISTA-16
- WHIMS